1. Scrip

Pfizer's Bourla: "I Think We Forgot What It Looks Like To Grow"

 
• By Jessica Merrill

The big pharma CEO reflected on his first year of leadership at Pfizer during the Forbes Healthcare Summit and talked about executing on a plan to deliver 6% growth through 2026. 

Business Growth Concept_1089895325_1200.jpg
bourla wants to double Pfizer's pipeline

Pfizer Inc. CEO Albert Bourla took over the top leadership spot from Ian Read a year ago, but has quickly executed on big changes poised to make Pfizer significantly smaller and faster growing. The chief exec looked back at his first year of leadership, and the state of the company, from the stage of the Forbes Healthcare Summit in New York City.

"I think we forgot what it looks like to grow," Bourla told attendees during a presentation on 5 December. "Growth...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.